Literature DB >> 24355265

Aspirin use and melanoma risk: a review of the literature.

Shannon Famenini1, Lorraine C Young2.   

Abstract

In view of the increasing incidence of melanoma, it is critical to find effective preventive approaches. Contradictory evidence has been reported with regard to the possible association of aspirin use and the risk of melanoma. We review these studies and seek to elucidate the mechanism by which aspirin may produce a chemoprotective effect against melanoma.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  CI; HR; NSAID; aspirin; confidence interval; hazard ratio; melanoma; nonsteroidal anti-inflammatory drugs

Mesh:

Substances:

Year:  2014        PMID: 24355265     DOI: 10.1016/j.jaad.2013.09.045

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

1.  Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer.

Authors:  Debashree Basudhar; Robert C Cheng; Gaurav Bharadwaj; Lisa A Ridnour; David A Wink; Katrina M Miranda
Journal:  Free Radic Biol Med       Date:  2015-02-04       Impact factor: 7.376

2.  Acetylsalicylic Acid Exerts Potent Antitumor and Antiangiogenic Effects in Cutaneous and Uveal Melanoma Cell Lines.

Authors:  Dominique Fausto de Souza; Thupten Tsering; Miguel N Burnier; Vasco Bravo-Filho; Ana Beatriz Toledo Dias; Mohamed Abdouh; Alicia Goyeneche; Julia Valdemarin Burnier
Journal:  Ocul Oncol Pathol       Date:  2020-11-04

3.  Acetylsalicylic acid inhibits the growth of melanoma tumors via SOX2-dependent-PAF-R-independent signaling pathway.

Authors:  Anita Thyagarajan; Jeremiah Saylae; Ravi P Sahu
Journal:  Oncotarget       Date:  2017-07-25

4.  Implications of Aspirin for Melanoma Treatment: A Short Perspective.

Authors:  Anita Thyagarajan; Ravi P Sahu
Journal:  J Mol Genet Med (Lond)       Date:  2017-08-17

5.  Tumor-preventing activity of aspirin in multiple cancers based on bioinformatic analyses.

Authors:  Diangeng Li; Peng Wang; Yi Yu; Bing Huang; Xuelin Zhang; Chou Xu; Xian Zhao; Zhiwei Yin; Zheng He; Meiling Jin; Changting Liu
Journal:  PeerJ       Date:  2018-09-26       Impact factor: 2.984

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.